Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAN-90806 in Neovascular AMD
NCT03479372Phase 2Completed
- Sponsor
- PanOptica
- Start
- Apr 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of PAN-90806 in neovascular age-related macular degeneration (NVAMD), sponsored by PanOptica. Started Apr 2018; status: completed.
02
Drugs
PAN-90806
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03479372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03479372.